Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are not suitable for a "standard chemotherapy regimen": The CASA randomized trial. The breast, Vol. 22(2), April 2013, p.130-7.
Crivellari, D., et al.
http://www.thebreastonline.com/article/PIIS0960977613000179/abstract?rss=yes
There is no optimal treatment for breast cancers lacking estrogen (ER) and progesterone (PgR) receptors in elderly women with co-morbidities that prevent use of “standard chemotherapy regimens” such as AC or CMF. The CASA trial studied pegylated liposomal doxorubicin and low dose, metronomic cyclophosphamide + methotrexate (CM) for older (>65), vulnerable women with operable, ER and PgR-negative breast cancer.
